Intraosseous Squamous Cell Carcinoma Associated with Denosumab-Induced Osteonecrosis of the Jaw
Source abstract
Abstract
Medication-related osteonecrosis of the jaw (MRONJ) has been associated with the use of different drugs administered in the treatment of malignant neoplasms or metastases and in antiresorptive therapies. Since 2010, denosumab, a monoclonal antibody whose mechanism of action is to prevent the activation of the RANK receptor on the surface of osteoclasts, has been associated with osteonecrosis of the jaw. Primary intraosseous squamous cell carcinoma (PIOSCC) is a rare neoplasm characterised by the presence of squamous cells within the maxillary or mandibular bone without an initial clinical association with the oral mucosa. We present a case of a PIOSCC in an osteonecrosis of the jaw related to a patient who received antiresorptive treatment with denosumab outlining the clinical and histopathological features of MRONJ and PIOSCC.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Bone health and treatments · Bone Tumor Diagnosis and Treatments · Cancer Diagnosis and Treatment
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Maxillofacial Surgery Department, Hospital Universitario HLA Moncloa, 28008 Madrid, Spain
Pathology Department, Hospital Universitario HLA Moncloa, 28008 Madrid, Spain
Faculty of Medicine, Murcia University, 30008 Murcia, Spain
Faculty of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain
Radiology Department, Hospital Puerta de Hierro, 28222 Madrid, Spain
References (15)
Show source-provided references
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries10.3322/caac.21660 ↗
2. Intraosseous carcinoma of the jaws: A clinicopathologic review. Part III: Primary intraosseous squamous cell carcinoma10.1002/hed.22922 ↗
3. Risk factors and prognosis for the primary intraosseous carcinoma of the jaw10.1016/j.ijom.2018.07.019 ↗
4. Pamidronate (Aredia) and zolendronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic10.1016/S0278-2391(03)00720-1 ↗
5. Diagnostic dilemma between medication-related osteonecrosis and oral squamous cell carcinoma in a mandibular lytic lesion10.1016/j.bjoms.2017.08.005 ↗
6. Medication-Related Osteonecrosis of the Jaw (MRONJ) due to Simvastatin: An Unusual Case Report10.29252/wjps.10.1.132 ↗
7. Denosumab Related Osteonecrosis of the Jaw with Spontaneous Necrosis of the Soft Palate: Report of a Life Threatening Case
8. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw—2014 update10.1016/j.joms.2014.04.031 ↗
9. Metastatic solid tumors to the jaw and oral soft tissue: A retrospective clinical analysis of 44 patients from a single institution10.1016/j.jcms.2016.05.013 ↗
10. Bisphosphonate and Medication-Related Osteonecrosis of the Jaw: A Review10.1055/s-0036-1592367 ↗
11. Manejo de la osteonecrosis maxilar asociada al uso de medicamentos en virtud de su estadio clínico: Análisis de 19 casos10.1016/j.maxilo.2017.06.001 ↗
12. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials10.1111/clr.12556 ↗
13. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases10.1093/annonc/mdr435 ↗
14. Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study10.1200/JCO.2010.29.7101 ↗
15. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: An analysis of data from patients with solid tumors10.1007/s00520-013-2022-1 ↗